Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Wednesday

Posted by Denise Davis on Aug 6th, 2024

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) is set to announce its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.76) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). On average, analysts expect Atea Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Atea Pharmaceuticals Stock Up 1.2 %

Atea Pharmaceuticals stock traded up $0.04 during mid-day trading on Tuesday, reaching $3.32. 55,927 shares of the company’s stock were exchanged, compared to its average volume of 344,931. The business’s fifty day simple moving average is $3.58 and its 200 day simple moving average is $3.81. The firm has a market capitalization of $279.62 million, a PE ratio of -1.66 and a beta of 0.17. Atea Pharmaceuticals has a one year low of $2.77 and a one year high of $4.60.

Insider Buying and Selling

In related news, Director Bruce Polsky sold 17,544 shares of Atea Pharmaceuticals stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $3.49, for a total transaction of $61,228.56. Following the sale, the director now directly owns 65,606 shares in the company, valued at $228,964.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 17.80% of the stock is currently owned by corporate insiders.

Atea Pharmaceuticals Company Profile

(Get Free Report)

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.